Nuvectra Corp (NASDAQ:NVTR) has been given an average recommendation of “Hold” by the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.00.
Several brokerages have recently commented on NVTR. ValuEngine lowered Nuvectra from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Raymond James lowered Nuvectra from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 13th. Finally, Zacks Investment Research lowered Nuvectra from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.
Several institutional investors have recently made changes to their positions in the company. Valeo Financial Advisors LLC acquired a new position in Nuvectra during the 3rd quarter worth about $30,000. Tower Research Capital LLC TRC lifted its stake in Nuvectra by 1,431.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,030 shares of the company’s stock worth $44,000 after acquiring an additional 12,179 shares in the last quarter. Edge Wealth Management LLC lifted its stake in Nuvectra by 24.9% during the 3rd quarter. Edge Wealth Management LLC now owns 50,140 shares of the company’s stock worth $68,000 after acquiring an additional 10,000 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Nuvectra by 304.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 33,857 shares of the company’s stock worth $110,000 after acquiring an additional 25,482 shares in the last quarter. Finally, Gamco Investors INC. ET AL lifted its stake in Nuvectra by 34.7% during the 3rd quarter. Gamco Investors INC. ET AL now owns 105,194 shares of the company’s stock worth $143,000 after acquiring an additional 27,100 shares in the last quarter. 75.17% of the stock is currently owned by institutional investors and hedge funds.
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
Read More: Asset Allocation
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.